Ropinirole, open preliminary observations of a dopamine agonist for refractory fibromyalgia [2]

Journal of Clinical Rheumatology

Volumn 9, Issue 4, 2003, Pages 277-279

  Holman, Andrew J ^a  

^a Pacific Rheumatology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; ROPINIROLE;

ADULT; CLINICAL ARTICLE; COMORBIDITY; DRUG EFFECT; FEMALE; FIBROMYALGIA; HOSPITALIZATION; HUMAN; LETTER; MALE; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; RETROSPECTIVE STUDY;

EID: 0041653316     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rhu.0000081264.26484.e5     Document Type: Letter

References (9)

1. Yunus M, Aldag J. Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study. BMJ. 1996;312:1339.
2. Moldofsky H, Scarisbrick P, England R, et al. Musculoskeletal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. Psycbosom Med. 1975;37:341-351.
3. Lentz MJ, Landis CA, Rothermel J, et al. Effects of selective slow wave sleep disruption on musculoskeletal pain and fatigue in middle-aged women. J Rheumatol. 1999;26:1586-1592.
4. Holman AJ. Effect of lorazepam on pain score for refractory fibromyalgia [abstract]. Arthritis Rheum. 1998;41(Suppl):A1359.
5. Holman AJ. Safety and efficacy of lorazepam for fibromyalgia after one year [abstract]. Arthritis Rheum. 1999;42(Suppl):A385.
6. Holman AJ. Safety and efficacy of the dopamine agonist, pramipexole, on pain score for refractory fibromyalgia [abstract]. Arthritis Rheum. 2000;43: A1599.
7. Holman AJ, Neiman RA, Ettlinger RE. Pramipexole for fibromyalgia: the first open label, multicenter experience [abstract]. Arthritis Rheum. 2002;46: A189.
8. Ondo W. Ropinirole for restless legs syndrome. Mov Disord. 1999;14:138-140.
9. SmithKline Beecham Pharmaceuticals. Product information on Requip (ropinirole hydrochloride). SmithKline Beecham Pharmaceuticals, 2003.